Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia

International Journal of Oncology

Volumn 40, Issue 2, 2012, Pages 418-426

  Wang, Qiang ^a   Zhou, Hong Sheng ^a   Huang, Kai Kai ^a   Jiang, Xue Jie ^a   Wu, Fu Qun ^a   Cao, Rui ^a   Yin, Chang Xin ^a   Liao, Li Bin ^a   Zheng, Zhong Xin ^a   He, Han ^a   Lin, Rong ^a   Yi, Zheng Shan ^a   Xu, Dan ^a   Yang, Mo ^a,b   Meng, Fan Yi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bortezomib; Cdh1; Chronic myeloid leukemia; Imatinib resistant; Tyrosine kinase inhibitor

Indexed keywords

BORTEZOMIB; IMATINIB; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; UVOMORULIN;

ADULT; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CELL CYCLE; CELL CYCLE ARREST; CELL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ADULT; ANTINEOPLASTIC AGENTS; BLAST CRISIS; BORONIC ACIDS; CADHERINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRAZINES; PYRIMIDINES; RNA INTERFERENCE; S-PHASE KINASE-ASSOCIATED PROTEINS; YOUNG ADULT;

EID: 84862971044     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1233     Document Type: Article

References (37)

1. Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356, 2000.
2. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R and Druker BJ: IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004, 2003. (Pubitemid 36302244)
3. Ye JY, Chan GCF, Qiao L, Lian QZ, Meng FY, Luo XQ, Khachigian LM, Ma M, Deng R, Chen JL, Chong BH and Yang M: Platelet-derived growth factor enhances platelet recovery in a murine model of radiation-induced thrombocytopenia and reduces apoptosis in megakaryocytes via its receptors and the PI3K/AKT pathway. Haematologica 95: 1745-1753, 2010.
4. Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, Hu P and Shen Z: Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 31: 1568-1575, 2009.
5. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D and Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362: 2260-2270, 2010.
6. Corey SJ: The hematologists' Maltese Falcon. Blood 115: 3179-3180, 2010.
7. Schemionek M, Elling C, Steidl U, Bäumer N, Hamilton A, Spieker T, Göthert JR, Stehling M, Wagers A, Huettner CS, Tenen DG, Tickenbrock L, Berdel WE, Serve H, Holyoake TL, Müller-Tidow C and Koschmieder S: BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 115: 3185-3195, 2010.
8. Calabretta B and Perrotti D: The biology of CML blast crisis. Blood 103: 4010-4022, 2004. (Pubitemid 38685338)
9. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Yehuda DB, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral A, Esseltine DL, Porter JB, Schenkein D and Anderson K: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005. (Pubitemid 41007864)
10. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y, Feng TT, Meng FY, Liu XL, Jiang QL, Chen XQ, Liu JL, Liu P, Chen Z, Chen SJ and Zhou GB: Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 16: e6257, 2009.
11. Liu QF, Xu XJ, Chen YK, Sun J, Zhang Y, Fan ZP, Xu D, Jiang QL, Wei YQ, Huang F, Feng R, Liu XL, Xu B and Meng FY: Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Ann Hematol 90: 331-341, 2011.
12. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL and Weissman IL: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351: 657-667, 2004. (Pubitemid 39063268)
13. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A and Reya T: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541, 2007. (Pubitemid 350199070)
14. Jamieson CH: Chronic myeloid leukemia stem cells. Hematology. Am Soc Hematol Educ Program pp436-442, 2008.
15. Skaar JR and Ano M: Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 21: 816-824, 2009.
16. Skaar JR and Pagano M: Cdh1: a master G0/G1 regulator. Nat Cell Biol 10: 755-757, 2008. (Pubitemid 351927702)
17. Nakayama KI and Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6: 369-381, 2006.
18. García-Higuera I, Manchado E, Dubus P, Cañamero M, Méndez J, Moreno S and Malumbres M: Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat Cell Biol 10: 802-811, 2008. (Pubitemid 351927709)
19. Engelbert D, Schnerch D, Baumgarten A and Wäsch R: The ubiquitin ligase APCcdh1 is required to maintain genome integrity in primary human cells. Oncogene 27: 907-917, 2008. (Pubitemid 351225382)
20. Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 65: 3264-3272, 2005.
21. Swerdlow, SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC Press, Lyon, p32, 2008.
22. Bystřicka D, Zemanová Z, Březinová J, Gančarčíková M, Grosová L, Sárová I, Izáková S, Berková A and Michalová K: The assessment of array comparative genomic hybridization in complex karyotype analyses. Folia Biologica (Praha) 56: 223-230, 2010.
23. Brothman AR, Persons DL and Shaffer LG: Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 127: 1-4, 2009.
24. Le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R and Gambacorti-Passerini C: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758-1766, 2000. (Pubitemid 30120840)
25. Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A and Pagano M: The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell 134: 256-267, 2008. (Pubitemid 352010329)
26. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J and Pandolfi PP: Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464: 374-379, 2010.
27. Zhou GS, Hu Z, Fang HT, Zhang FX, Pan XF, Chen XQ, Hu AM, Xu L and Zhou GB: Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res 35: 214-218, 2011.
28. Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM and Perez-Soler R: PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1: 841-849, 2002.
29. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM and Perez-Soler R: Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154, 2003. (Pubitemid 36323724)
30. Kip1 signaling axis. Cancer Res 68: 9015-9023, 2008.
31. Fujita T, Liu W, Doihara H, Date H and Wan Y: Dissection of the APCCdh1-Skp2 cascade in breast cancer. Clin Cancer Res 14: 1966-1975, 2008. (Pubitemid 351551105)
32. Chen JY, Wang MC and Hung WC: Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. Leuk Res 33: 1520-1524, 2009.
33. Chen JY, Wang MC and Hung WC: Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. J Cell Physiol 226: 407-413, 2011.
34. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J and Rousselot P: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035, 2010.
35. Kuo YL and Giam CZ: Activation of the anaphase promoting complex by HTLV-1 tax leads to senescence. EMBO J 25: 1741-1752, 2006.
36. Liu B, Hong S, Tang Z, Yu H and Giam CZ: HTLV-I Tax directly binds the Cdc20-ssociated anaphase-promoting complex and activates it ahead of schedule. Proc Natl Acad Sci USA 102: 63-68, 2005. (Pubitemid 40094429)
37. Liu M, Yang L, Zhang L, Liu B, Merling R, Xia Z and Giam CZ: Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle. J Virol 82: 8442-8455, 2008.